what they said (Hover the mouse cursor over underlined words for more info)

TORONTO - Patients taking a brand new type of HIV drug have shown a quick reduction in the number of viruses circulating in their bloodstream, according to early data from a clinical trial that is to be announced at the International AIDS Conference in Toronto later this week.
The drug belongs to a long-awaited new class of HIV medications known as integrase inhibitors. They work to block the enzyme the virus uses to integrate its genetic material into the DNA of a host's cell and make copies of itself....

The original article can be found at: http://www.theglobeandmail.com/servlet/story/RTGAM.20060813.aids-drug14/BNStory/Front/

The original article can found in the Media Doctor archives.

how did it rate? (more information)

what we said (Hover the mouse cursor over underlined words for more info)

This journalist provided an unusually descriptive account of the details of the clinical trial including independent commentary on the significance of the research. It was particularly notable that the inclusion criteria were given for study participants. Some mention of the expected timeline for the drug to enter the market would have been useful to the reader as would have a better quantification of the potential harms involved.

public forum

voice your opinion in the forum

• All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
• If you provide your email address it will not be displayed to the general public.
• Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
• Required fields are marked with an asterisk (*).